Clinical Study of GP Regimen Plus Gensing Rg3 in Treatment of Advanced Non-small Cell Lung Cancer

Objective To study the clinical effect and toleration of Rg3 combination with chemotherapy regimen—GP in patients with advanced non-small cell lung cancer (NSCLC). Methods Seventy-seven patients were divided into two groups randomly.Thirty-nine patients as treatment group,treated by Rg3 plus GP regimen,and thirty-eight patients as the control group,only treated by GP regimen. Results The response rate was 48.7% in treatment group and 36.8% in control,The clinical benefit rate (disease control rate) was 82.1% and 63.2% respectively (P<0.05). Conclusion Rg3 combined with GP regimen could increase the therapeutic effects and decrease the side effects of chemotherapy in the patients with advanced non-small cell lung cancer.